药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Fezakinumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Fezakinumab.
Tiludronic acid
Ensituximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ensituximab.
Tiludronic acid
Tanezumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tanezumab.
Tiludronic acid
Labetuzumab govitecan
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Labetuzumab govitecan.
Tiludronic acid
Vanucizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Vanucizumab.
Tiludronic acid
GS-5745
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with GS-5745.
Tiludronic acid
Luspatercept
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Luspatercept.
Tiludronic acid
Aducanumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Aducanumab.
Tiludronic acid
Ascrinvacumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ascrinvacumab.
Tiludronic acid
Cixutumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Cixutumumab.
Tiludronic acid
Inclacumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Inclacumab.
Tiludronic acid
Polatuzumab vedotin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Polatuzumab vedotin.
Tiludronic acid
Etaracizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Etaracizumab.
Tiludronic acid
Ganitumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ganitumab.
Tiludronic acid
Zalutumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Zalutumumab.
Tiludronic acid
Etrolizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Etrolizumab.
Tiludronic acid
Tralokinumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tralokinumab.
Tiludronic acid
Dupilumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dupilumab.
Tiludronic acid
Fasinumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Fasinumab.
Tiludronic acid
Simtuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Simtuzumab.